Deutsche Bank downgraded the New Jersey-based nutritional supplement retailing company to "hold" from "buy," and set a price target of $43, down from its previous mark of $50.
"[Vitamin Shoppe]'s 3Q14 missed on the top line and on expenses, the comp guidance for 4Q is disappointing, [selling, general & administrative expenses] in 3Q was very disappointing and FY15 comments indicate higher SG&A will not abate, and FY15 preliminary guidance comments brings our already-below-the-street EPS down by an additional $0.06," analysts at Deutsche Bank said.
Must Read: Warren Buffett's 25 Favorite Stocks
Sterne Agee downgraded Vitamin Shoppe to "neutral" from "buy," and cut the price target to $42 from $53, pointing to a potential downside of 8.16% from the company's current price.
Separately, TheStreet Ratings team rates VITAMIN SHOPPE INC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate VITAMIN SHOPPE INC (VSI) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income."